OncoVanta Therapeutics is a precision oncology company developing a TCR-T cell therapy platform targeting cancers driven by mutant TP53, specifically the R175H mutation. The company is advancing preclinical programs focused on TCR engineering, immune assay development, and functional cytotoxicity testing to generate translational datasets supporting IND-enabling studies. Its platform seeks to address a major unmet need in solid tumors where p53 mutations are prevalent and currently lack targeted immunotherapies.
Funding
Funding not disclosed
Founders
Product
Problem
Mutations in the TP53 gene, particularly the R175H hotspot mutation, are among the most common drivers of aggressive solid tumors and are associated with poor prognosis and resistance to conventional therapies. Despite their prevalence, no targeted immunotherapies currently exist that specifically recognize and eliminate cancer cells presenting mutant p53 peptides on HLA molecules, leaving a significant patient population without viable treatment options.
Solution
OncoVanta Therapeutics is developing a mutant TP53-targeted TCR-T cell therapy platform designed to redirect T cells against cancer cells expressing the R175H p53 mutation. The company’s preclinical programs focus on TCR engineering to generate high-affinity, mutation-specific T-cell receptors, alongside immune assay development and functional cytotoxicity testing to validate therapeutic efficacy. OncoVanta is generating translational datasets that include functional T-cell responses and specificity profiles, which will support advancement toward IND-enabling studies. The platform aims to provide a personalized, cell-based immunotherapy option for solid tumors characterized by this specific genetic alteration.
Target Audience
Primary customers are oncology drug development partners, licensing collaborators, and clinical investigators focused on precision immunotherapies for solid tumors harboring TP53 mutations.
Features
- TCR engineering platform specifically targeting the TP53 R175H hotspot mutation presented on HLA molecules
- Preclinical immune assay development including functional cytotoxicity testing to assess T-cell killing potency
- Translational dataset generation designed to support regulatory submission and IND-enabling study progression
- Cellular immunology expertise applied to optimize T-cell receptor affinity and specificity against mutant p53 peptides
- Biomarker-driven research strategy aligned with patient selection and translational oncology programs